The Cardiovascular Impact of Carfilzomib in Multiple Myeloma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Luthi, Jennifer [1 ]
Belohlavek, Marek [1 ]
Mookadam, Farouk [1 ]
Mayo, Angela [1 ]
Fonseca, Rafael [1 ,2 ]
Bergsagel, P. Leif
Reeder, Craig B. [1 ]
Mikhael, Joseph R. [1 ]
Stewart, Keith [2 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Carfilzomib induced cardiotoxicity in a multiple myeloma patient
    Arnold Méndez-Toro
    Cándida Díaz-Brochero
    Estivalis Acosta-Gutiérrez
    Cardio-Oncology, 6
  • [22] Carfilzomib induced cardiotoxicity in a multiple myeloma patient
    Mendez-Toro, Arnold
    Diaz-Brochero, Candida
    Acosta-Gutierrez, Estivalis
    CARDIO-ONCOLOGY, 2020, 6 (01)
  • [23] Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    San-Miguel, Jesus F.
    Ludwig, Heinz
    Wang, Michael
    Maisnar, Vladimr
    Minarik, Jiri
    Bensinger, William I.
    Mateos, Maria-Victoria
    Ben-Yehuda, Dina
    Kukreti, Vishal
    Zojwalla, Naseem
    Tonda, Margaret E.
    Yang, Xinqun
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 142 - 152
  • [24] Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
    Chari, Ajai
    Stewart, A. Keith
    Russell, Stuart D.
    Moreau, Philippe
    Herrmann, Joerg
    Banchs, Jose
    Hajek, Roman
    Groarke, John
    Lyon, Alexander R.
    Batty, George N.
    Ro, Sunhee
    Huang, Mei
    Iskander, Karim S.
    Lenihan, Daniel
    BLOOD ADVANCES, 2018, 2 (13) : 1633 - 1644
  • [25] BUDGET IMPACT ANALYSIS OF CARFILZOMIB FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA (MM) IN MEXICO
    Alva, M. E.
    Campioni, M.
    Zamora, J.
    Giannopoulou, A.
    VALUE IN HEALTH, 2015, 18 (07) : A818 - A818
  • [26] Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
    Astarita, Anna
    Mingrone, Giulia
    Airale, Lorenzo
    Vallelonga, Fabrizio
    Covella, Michele
    Catarinella, Cinzia
    Cesareo, Marco
    Bruno, Giulia
    Leone, Dario
    Giordana, Carlo
    Cetani, Giusy
    Salvini, Marco
    Gay, Francesca
    Bringhen, Sara
    Rabbia, Franco
    Veglio, Franco
    Milan, Alberto
    CANCERS, 2021, 13 (07)
  • [27] CAROTID-FEMORAL PULSE WAVE VELOCITY AND CARDIOVASCULAR EVENTS IN MULTIPLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB
    Bruno, G.
    Maffei, I
    Iannaccone, A.
    Crea, T.
    Salvini, A.
    Gay, F.
    Bringhen, S.
    Veglio, F.
    Milan, A.
    HAEMATOLOGICA, 2018, 103 : 33 - 33
  • [28] Carfilzomib and Pomalidomide: Recent Advances in the Treatment of Multiple Myeloma
    Highsmith, Kaitlin N.
    Chen, Sheree E.
    Horowitz, Sandy
    PHARMACOTHERAPY, 2014, 34 (09): : 927 - 940
  • [29] Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma
    Tantawy, Marwa
    Langaee, Taimour
    Wang, Danxin
    Rubinstein, Samuel M.
    Cornell, Robert F.
    Lenihan, Daniel
    Fradley, Michael G.
    Gong, Yan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [30] Multiple Myeloma Third Relapse Regimen with Carfilzomib approved
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 214 - 214
12345